Stock Track | Ardelyx Soars 14.37% After-Hours on Strong Q3 Results and Raised Guidance

Stock Track

2025/10/31

Shares of Ardelyx (NASDAQ: ARDX) surged 14.37% in after-hours trading following the release of the company's third quarter financial results that exceeded analyst expectations and showcased robust growth for its key products.

The biopharmaceutical company reported total revenue of $110.329 million for Q3 2025, beating the analyst consensus estimate of $100.878 million by 9.37%. This represents a significant 12.30% increase compared to sales of $98.241 million in the same period last year. The strong performance was primarily driven by impressive growth in IBSRELA sales and steady progress for XPHOZAH.

IBSRELA, Ardelyx's treatment for irritable bowel syndrome with constipation (IBS-C), generated $78.2 million in Q3 revenue, reflecting a remarkable 92% year-over-year growth. Based on this strong performance, the company raised its full-year 2025 revenue guidance for IBSRELA to between $270-275 million. Meanwhile, XPHOZAH, used to reduce serum phosphorus in adults with chronic kidney disease on dialysis, recorded $27.4 million in Q3 revenue, up 9% compared to Q2 2025. The company also announced progress on a pipeline program for a next-generation NHE3 inhibitor, showcasing potential for future growth across multiple therapeutic areas.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1102260286"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102260286\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102260286?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 04:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102260286","market":"us","top_or_hot":-1,"title":"Stock Track | Ardelyx Soars 14.37% After-Hours on Strong Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>Shares of Ardelyx (NASDAQ: ARDX) surged 14.37% in after-hours trading following the release of the company's third quarter financial results that exceeded analyst expectations and showcased robust growth for its key products.</p>\n\n<p>The biopharmaceutical company reported total revenue of $110.329 million for Q3 2025, beating the analyst consensus estimate of $100.878 million by 9.37%. This represents a significant 12.30% increase compared to sales of $98.241 million in the same period last year. The strong performance was primarily driven by impressive growth in IBSRELA sales and steady progress for XPHOZAH.</p>\n\n<p>IBSRELA, Ardelyx's treatment for irritable bowel syndrome with constipation (IBS-C), generated $78.2 million in Q3 revenue, reflecting a remarkable 92% year-over-year growth. Based on this strong performance, the company raised its full-year 2025 revenue guidance for IBSRELA to between $270-275 million. Meanwhile, XPHOZAH, used to reduce serum phosphorus in adults with chronic kidney disease on dialysis, recorded $27.4 million in Q3 revenue, up 9% compared to Q2 2025. The company also announced progress on a pipeline program for a next-generation NHE3 inhibitor, showcasing potential for future growth across multiple therapeutic areas.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ardelyx Soars 14.37% After-Hours on Strong Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ardelyx Soars 14.37% After-Hours on Strong Q3 Results and Raised Guidance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-10-31 04:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Ardelyx (NASDAQ: ARDX) surged 14.37% in after-hours trading following the release of the company's third quarter financial results that exceeded analyst expectations and showcased robust growth for its key products.</p>\n\n<p>The biopharmaceutical company reported total revenue of $110.329 million for Q3 2025, beating the analyst consensus estimate of $100.878 million by 9.37%. This represents a significant 12.30% increase compared to sales of $98.241 million in the same period last year. The strong performance was primarily driven by impressive growth in IBSRELA sales and steady progress for XPHOZAH.</p>\n\n<p>IBSRELA, Ardelyx's treatment for irritable bowel syndrome with constipation (IBS-C), generated $78.2 million in Q3 revenue, reflecting a remarkable 92% year-over-year growth. Based on this strong performance, the company raised its full-year 2025 revenue guidance for IBSRELA to between $270-275 million. Meanwhile, XPHOZAH, used to reduce serum phosphorus in adults with chronic kidney disease on dialysis, recorded $27.4 million in Q3 revenue, up 9% compared to Q2 2025. The company also announced progress on a pipeline program for a next-generation NHE3 inhibitor, showcasing potential for future growth across multiple therapeutic areas.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"","article_id":"1102260286","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102260286","pubTimestamp":1761856565,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ardelyx (NASDAQ: ARDX) surged 14.37% in after-hours trading following the release of the company's third quarter financial results that exceeded analyst expectations and showcased robust...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"个股赛道|Ardelyx盘后大涨14.37%Q3业绩强劲且指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1},"content_text":"Shares of Ardelyx (NASDAQ: ARDX) surged 14.37% in after-hours trading following the release of the company's third quarter financial results that exceeded analyst expectations and showcased robust growth for its key products.\nThe biopharmaceutical company reported total revenue of $110.329 million for Q3 2025, beating the analyst consensus estimate of $100.878 million by 9.37%. This represents a significant 12.30% increase compared to sales of $98.241 million in the same period last year. The strong performance was primarily driven by impressive growth in IBSRELA sales and steady progress for XPHOZAH.\nIBSRELA, Ardelyx's treatment for irritable bowel syndrome with constipation (IBS-C), generated $78.2 million in Q3 revenue, reflecting a remarkable 92% year-over-year growth. Based on this strong performance, the company raised its full-year 2025 revenue guidance for IBSRELA to between $270-275 million. Meanwhile, XPHOZAH, used to reduce serum phosphorus in adults with chronic kidney disease on dialysis, recorded $27.4 million in Q3 revenue, up 9% compared to Q2 2025. The company also announced progress on a pipeline program for a next-generation NHE3 inhibitor, showcasing potential for future growth across multiple therapeutic areas.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}